Pay Per View: Why Fees for DTC Might Fly
This article was originally published in RPM Report
Executive Summary
The pharma industry is promising to preclear its ads with FDA. The problem is, FDA's ad review group is already overworked. Some in industry think the answer is to expand the user fee program to include fees for DTC.